InsidersTradesSigma
昭衍新药 Stock: price and insider trades · China · SSE / SZSE (CSRC)
Track the 昭衍新药 share price and the full insider trade history of the company, a listed equity based in China. Shares are quoted on CN CN, under the oversight of SSE / SZSE (CSRC). Operating in the Health Care sector, 昭衍新药 has published 44 public disclosures. Market capitalisation: €24.3bn. The latest transaction was disclosed on 30 September 2025 (Sale). Among the most active insiders: 左从林. All data is accessible without an account.
44
Insider Decl.
0
Thresholds
·
1 ops.
Buy Volume
€84,498
43 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 15,468 of 25,564 companies
45.4
score / 100
Value28
Quality63
FCF yld1.0%
Earn yld1.0%
EV/EBITDA59.9x
ROE5.9%
Gross mgn21%
Net mgn18%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 30 September 2025
Declarations44 total
25 of 44 declarations
About 昭衍新药
Zhaoyan New Drug is a company focused on the research and development of pharmaceuticals. It is listed on the XSHG market.